COSENTYX

What COSENTYX does

COSENTYX (secukinumab) is a prescription biologic medication developed and marketed by Novartis Pharmaceuticals Corporation, a wholly-owned US subsidiary of Novartis AG (NYSE: NVS). The product is a monoclonal antibody that selectively binds and inhibits interleukin-17A (IL-17A), a cytokine implicated in the inflammatory cascade of several autoimmune diseases. COSENTYX is administered either by subcutaneous self-injection using proprietary delivery devices (Sensoready Pen 150 mg, UnoReady Pen 300 mg, and 75 mg/150 mg prefilled syringes) or by 30-minute intravenous infusion at a provider site, with dosing individualized by indication and body weight.

The franchise is FDA-approved across six therapeutic areas: moderate to severe plaque psoriasis (adults and pediatric patients 6+), active psoriatic arthritis (adults and pediatric 2+), active ankylosing spondylitis (adults and pediatric 12+), active non-radiographic axial spondyloarthritis, moderate to severe hidradenitis suppurativa (adults and pediatric 12+), and enthesitis-related arthritis / juvenile psoriatic arthritis (pediatric 4+ and 2+ respectively). The asset has accumulated over 18 years of clinical trial experience and more than 6 million US prescriptions since its initial 2015 approval, making it the #1 prescribed IL-17A inhibitor in the United States.

Commercially, COSENTYX is sold through a tri-channel distribution architecture: a specialty pharmacy network for insured patients, a direct-to-patient pharmacy operated by ASPN/Thrifty White for self-pay customers at a 55-57% discount off list, and provider-administered IV infusion in clinical settings. List pricing is approximately $8,492 per month for the 300 mg self-injection and $4,489 per IV infusion as of January 2026. Patient access is supported by a layered financial-assistance stack including the Co-Pay Plus program (eligible privately insured patients pay as little as $0), the Covered Until You're Covered bridge program (up to 2 years of free drug for denied claims), and the Novartis Patient Assistance Foundation for the uninsured. The product is marketed through cosentyx.com, YouTube, Facebook, and Instagram, with a sales motion routed through rheumatologists, dermatologists, and other prescribing specialists.

Name

COSENTYX

Legal name

Novartis Pharmaceuticals Corporation

Website

https://cosentyx.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

COSENTYX (secukinumab) is Novartis's IL-17A-targeting biologic for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, nr-axSpA, hidradenitis suppurativa, and pediatric arthritis, delivered via self-injection pens, prefilled syringes, or IV infusion to patients in the United States.

Ownership category

akta.pro rank

Product category

Biologic Pharmaceuticals

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Biologic immunotherapy
• IL-17A inhibitor
• Monoclonal antibody therapy
• Prescription pharmaceuticals
• Autoimmune disease treatment

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Operations, Personnel

Revenue model

1. Prescription Pharmaceutical Sales: COSENTYX is sold as a prescription biologic medication through specialty pharmacies and direct-to-patient channels. Revenue is generated through product sales at list prices, with patients or their insurance paying for the medication.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

COSENTYX (secukinumab) is a prescription biologic monoclonal antibody medication that targets and blocks the IL-17A molecule to reduce inflammation in autoimmune conditions. It is FDA-approved for six indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, and enthesitis-related arthritis, and is available as self-injection (Sensoready Pen, UnoReady Pen, Prefilled Syringe) or 30-minute IV infusion. The product is supported by comprehensive patient assistance including Co-Pay Plus, Covered Until You're Covered bridge program, and a direct-to-patient purchase option through ASPN Pharmacies.

Product overview

COSENTYX is a prescription biologic medication (secukinumab) that functions as an IL-17A inhibitor to treat multiple inflammatory conditions. The product portfolio consists of the core COSENTYX drug available through three self-injection delivery devices (Sensoready Pen 150mg, UnoReady Pen 300mg, and Prefilled Syringes in 75mg and 150mg doses) and IV infusion. COSENTYX is FDA-approved across six indication areas: plaque psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS), and enthesitis-related arthritis (ERA). The product is supported by comprehensive patient services including the Novartis Patient Support Program, Co-Pay Plus assistance, the Covered Until You're Covered bridge program, and a Direct-to-Patient option through ASPN Pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

• COSENTYX Sensoready Pen: Self-injection device for 150 mg dose
• COSENTYX UnoReady Pen
• COSENTYX Prefilled Syringe
• Co-Pay Plus
• Covered Until You're Covered (Bridge Program)
• Novartis Patient Support

Products and services

• COSENTYX (secukinumab) Prescription biologic medication containing secukinumab, an IL-17A inhibitor used to treat multiple inflammatory conditions including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa, and enthesitis-related arthritis. Available in self-injection devices (Sensoready Pen, UnoReady Pen, Prefilled Syringe) or IV infusion.
• COSENTYX Sensoready Pen (150 mg)

Quantifiable outcome

• 41% of patients saw at least 40% improvement in nr-axSpA symptoms at 16 weeks vs 28% placebo
• +5 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• ASPN PharmaciescoreChannel Partner/ Reseller/ DistributorASPN Pharmacies partners with pharmaceutical manufacturers to streamline the prescription process and help patients get access to medication. They facilitate the direct-to-patient purchase option for COSENTYX, allowing self-pay patients to enroll online and receive medication shipped directly to their homes.
• Thrifty White PharmacycoreChannel Partner/ Reseller/ DistributorThrifty White Pharmacy is the fulfillment partner for COSENTYX direct purchases made through ASPN Pharmacies. All prescription purchases are dispensed through this licensed pharmacy.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• UCB (Bimzelx / bimekizumab): UCB's Bimzelx is an IL-17A/F dual inhibitor approved for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa, putting it in direct competition with COSENTYX across all major immunology indications including the newly competitive HS market.
• AbbVie (Skyrizi / risankizumab): AbbVie's Skyrizi is an IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and is the primary biologic competitor to COSENTYX in HS. Both products target the same inflammatory disease pathways and compete for the same specialty prescriber audience.
• Sanofi / Regeneron (Dupixent / dupilumab): Dupixent is an IL-4/IL-13 inhibitor approved across multiple type 2 inflammatory conditions including atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, and chronic spontaneous urticaria, competing with COSENTYX for the same autoimmune/atopic patient pool and prescriber mindshare in specialty immunology.
• Eli Lilly (Taltz / ixekizumab): Eli Lilly markets Taltz, an IL-17A inhibitor approved for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and nr-axSpA — directly mirroring COSENTYX's indications and competing head-to-head in the IL-17 class with the same mechanism of action.
• Bristol Myers Squibb (Sotyktu / deucravacitinib): BMS's Sotyktu is an oral allosteric TYK2 inhibitor approved for plaque psoriasis, representing a competing modality (oral small molecule) against COSENTYX's injectable biologic in the same patient population.
• Johnson & Johnson (Tremfya / guselkumab): J&J's Tremfya is an IL-23 inhibitor approved for plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, competing directly with COSENTYX in PsO and PsA and increasingly in broader rheumatology indications.

Broad incumbents

• Amgen (Enbrel / etanercept): Amgen's Enbrel is a long-established TNF inhibitor used in plaque psoriasis, PsA, and ankylosing spondylitis, representing a broader rheumatology/dermatology incumbent against which COSENTYX has built share over the past decade.
• Pfizer (Xeljanz / tofacitinib): Pfizer's Xeljanz is an oral JAK inhibitor used in rheumatoid arthritis, PsA, and ulcerative colitis, competing with COSENTYX in PsA and serving as a broader rheumatology competitor in inflammatory disease prescribing decisions.
• AbbVie (Humira / adalimumab): Humira is the legacy TNF-alpha inhibitor that historically dominated psoriasis, PsA, AS, and HS, and was the standard-of-care biologic COSENTYX displaced. It remains a broad incumbent reference point for the immunology franchise even after biosimilar entry.

Others

• Novartis AG (parent): Novartis AG is the publicly traded parent of Novartis Pharmaceuticals Corporation and operates the broader pharma portfolio (including Cosentyx, Kesimpta, and other immunology assets); included as a parent/ecosystem reference point rather than a direct product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights1 record

Customer concentration

• Xx.com/cosentyxusonly
• YouTubeyoutube.com/channel/UCDpSL-i3cQctS0FfNRBhEgQ
• Facebookfacebook.com/COSENTYXHCP
• Instagraminstagram.com/cosentyxsecukinumab/?igshid=1hmioy2761uae

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about COSENTYX